An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C and compensated cirrhosis patients with the prescribing pattern of vitaminD plus peginterferon alpha-2a /ribavirin. - The prescribing pattern of vitaminD plus peginterferon alfa-2a/ribavirin for treatment of chronic hepatitis C and compensated cirrhosis patients.

Saitama Medical University0 个研究点目标入组 80 人开始时间: 2012年7月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients were excluded 1)Women of childbearing potential and pregnancy, lactating woman 2) allergic to ribavirin or nucleoside analogues 3)an uncontrollable heart trouble (myocardial infarction, heart failure, or arrhythmia) 4)hemoglobinopathy(thalassemia, sickle cell disease) 5) severe renal disease, Ccr <50ml/min 6) severe depression or psychosomatic disorders 7)severe liver disease 8) autoimmune hepatitis or HBV 9) drug allergy against interferon 10) Allergic to vaccine or biological preparations 11) Concomitant herbal medication of Sho-saikoto 12) history of interstitial pneumonia 13) high-dose lipid soluble vitamin agents using patients. 14)Other conditions considered inappropriate by attending physician

发起方